Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
106M
-
Number of holders
-
145
-
Total 13F shares, excl. options
-
49.5M
-
Shares change
-
-10M
-
Total reported value, excl. options
-
$141M
-
Value change
-
-$233M
-
Put/Call ratio
-
0.36
-
Number of buys
-
79
-
Number of sells
-
-104
-
Price
-
$2.84
Significant Holders of Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX) as of Q1 2024
238 filings reported holding AMLX - Amylyx Pharmaceuticals, Inc. - COMMON STOCK as of Q1 2024.
Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX) has 145 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.5M shares
of 106M outstanding shares and own 46.53% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (5.35M shares), BlackRock Inc. (4.47M shares), GOLDMAN SACHS GROUP INC (2.94M shares), MILLENNIUM MANAGEMENT LLC (2.47M shares), MORGAN STANLEY (2.07M shares), STATE STREET CORP (2.06M shares), FRANKLIN RESOURCES INC (1.86M shares), Boxer Capital, LLC (1.5M shares), TWO SIGMA INVESTMENTS, LP (1.43M shares), and CITADEL ADVISORS LLC (1.33M shares).
This table shows the top 145 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.